The START Center for Cancer Research shared on LinkedIn: .
“Don’t miss our upcoming webinar, “Overcoming Resistance: Enhancing CDK4/6 Inhibitor Efficacy in Advanced Breast Cancer Treatment”, on July 9th at 3 PM ET.
Led by Michael Wick, Chief Scientific Officer at XenoSTART, this session will cover:
– Key insights into FDA-approved CDK4/6 inhibitors
– Mechanisms of resistance in ER+ breast cancer
– Strategies for re-sensitizing resistant patients through combination therapy
Register today.”
Source: The START Center for Cancer Research/LinkedIn